<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182518</url>
  </required_header>
  <id_info>
    <org_study_id>262.254</org_study_id>
    <nct_id>NCT02182518</nct_id>
  </id_info>
  <brief_title>Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis</brief_title>
  <official_title>Double-blind, Randomized, Parallel Trial to Evaluate the Clinical Efficacy and Safety of Epinastine 10 mg + Pseudoephedrine 120 mg SR, Twice a Day, Versus Epinastine 10 mg Alone, Twice a Day, in the Treatment of Outpatients With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the clinical efficacy and safety of Epinastine 10 mg +&#xD;
      Pseudoephedrine 120 mg slow release (SR) administered twice a day, compared to Epinastine 10&#xD;
      mg alone administered twice daily.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Classification of severity of nasal blockage by Visual Analog Scale (VAS)</measure>
    <time_frame>at the end of weeks 1, 2, 3, 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory alterations</measure>
    <time_frame>day 14, 28 and 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of premature discontinuations of the study due to adverse events</measure>
    <time_frame>up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of all adverse events</measure>
    <time_frame>up to 5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily evaluation of the nasal blockage by the patient</measure>
    <time_frame>daily up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classification of the severity of the symptoms by the investigator</measure>
    <time_frame>at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in nasal physical examination</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rhinorrhea symptoms evaluated by investigator</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pruritus symptoms evaluated by investigator</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sneezing symptoms evaluated by investigator</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lacrimation symptoms evaluated by investigator</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rhinorrhea symptoms evaluated by patient using VAS</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pruritus symptoms evaluated by patient using VAS</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sneezing symptoms evaluated by patient using VAS</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lacrimation symptoms evaluated by patient using VAS</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>Epinastine + Pseudoephedrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinastine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinastine</intervention_name>
    <arm_group_label>Epinastine</arm_group_label>
    <arm_group_label>Epinastine + Pseudoephedrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine</intervention_name>
    <arm_group_label>Epinastine + Pseudoephedrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo during run-in period</description>
    <arm_group_label>Epinastine</arm_group_label>
    <arm_group_label>Epinastine + Pseudoephedrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female outpatients&#xD;
&#xD;
          -  Over 12 years old&#xD;
&#xD;
          -  Patients who have granted their written informed consent, personally or by a legal&#xD;
             representative, to be part of the study and in accomplishment of the model of informed&#xD;
             consent approved by the Ethic Committee of the institution&#xD;
&#xD;
          -  Patients with an established diagnosis of allergic perennial rhinitis under the&#xD;
             clinical criteria (allergic to one or more allergens)&#xD;
&#xD;
          -  Patients with moderate or complete nasal blockage characterizes by ≥50 mm in the VAS&#xD;
             for this parameter during visits 1 and 2&#xD;
&#xD;
          -  Patients with positive (≥3 mm compared to the negative control) skin test (&quot;Prick&#xD;
             Test&quot;) to one or more of the following allergens:&#xD;
&#xD;
               -  Dermatophagoides pteronyssinus&#xD;
&#xD;
               -  Dermatophagoides farinae&#xD;
&#xD;
               -  Blomia tropicalis&#xD;
&#xD;
               -  Alternaria alternata&#xD;
&#xD;
               -  Cladosporium herbarum&#xD;
&#xD;
               -  Aspergillus fumigatus&#xD;
&#xD;
               -  Penicillium notatum&#xD;
&#xD;
               -  cat's fur&#xD;
&#xD;
               -  dog's fur&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast feeding women, or women without contraceptive method who:&#xD;
&#xD;
               -  are not in the postmenopausal period and/or&#xD;
&#xD;
               -  have not been submitted to bilateral tubal ligation or hysterectomy and/or&#xD;
&#xD;
               -  are not under one of the following contraceptive control:&#xD;
&#xD;
                    -  oral contraceptive&#xD;
&#xD;
                    -  IUD (intrauterine device)&#xD;
&#xD;
                    -  diaphragm&#xD;
&#xD;
          -  Patients unable to understand, accept or follow the protocol instructions&#xD;
&#xD;
          -  History of serious adverse events with antihistamines&#xD;
&#xD;
          -  Patients under treatment with calcium antagonists or other antihypertensive drugs&#xD;
&#xD;
          -  Patients under treatment with digitalis&#xD;
&#xD;
          -  Patients under treatment with MAO (monoamine oxidase) inhibitors&#xD;
&#xD;
          -  Patients under treatment with sympathicomimetics&#xD;
&#xD;
          -  Patients that have received any of the following drugs during the periods specified&#xD;
             below, before visit 1:&#xD;
&#xD;
               -  Inhaled/Topics&#xD;
&#xD;
                    -  short acting β2 agonists (12 hours)&#xD;
&#xD;
                    -  long acting β2 agonists (48 hours)&#xD;
&#xD;
                    -  ipratropium bromide (12 hours)&#xD;
&#xD;
                    -  nasal drops without vasoconstrictors (3 days)&#xD;
&#xD;
                    -  DSCG (disodium cromoglycate) (3 days)&#xD;
&#xD;
                    -  nedocromil (7 days)&#xD;
&#xD;
                    -  nasal drops with vasoconstrictors (7 days)&#xD;
&#xD;
                    -  azelastine (14 days)&#xD;
&#xD;
                    -  levocabastine (14 days)&#xD;
&#xD;
                    -  corticosteroids (30 days)&#xD;
&#xD;
                    -  corticosteroids on the site of Prick test (3 months)&#xD;
&#xD;
                    -  other investigational drug (3 months)&#xD;
&#xD;
               -  Oral&#xD;
&#xD;
                    -  short acting β2 agonists (18 hours)&#xD;
&#xD;
                    -  short acting theophylline (24 hours)&#xD;
&#xD;
                    -  phenothiazines (48 hours)&#xD;
&#xD;
                    -  long acting theophylline (72 hours)&#xD;
&#xD;
                    -  anticholinergics (7 days)&#xD;
&#xD;
                    -  antihistamines (except astemizole) (7 days)&#xD;
&#xD;
                    -  MAO (monoamine oxidase) inhibitors (14 days)&#xD;
&#xD;
                    -  corticosteroids (30 days)&#xD;
&#xD;
                    -  ketotifen (3 months)&#xD;
&#xD;
                    -  imipramine (30 days)&#xD;
&#xD;
                    -  astemizole (2 months)&#xD;
&#xD;
                    -  other investigational drugs (3 months)&#xD;
&#xD;
               -  Parenteral&#xD;
&#xD;
                    -  aminophylline (24 hours)&#xD;
&#xD;
                    -  phenothiazines (48 hours)&#xD;
&#xD;
                    -  antihistamines (7 days)&#xD;
&#xD;
                    -  corticosteroids (30 days)&#xD;
&#xD;
                    -  imipramine (30 days)&#xD;
&#xD;
                    -  other investigational drugs (3 months)&#xD;
&#xD;
          -  Patients under desensitization therapy&#xD;
&#xD;
          -  Patients under therapy with antibiotics&#xD;
&#xD;
          -  Patients with non compensate endocrine disease&#xD;
&#xD;
          -  Patients with atrophic rhinitis&#xD;
&#xD;
          -  Patients with rhinitis due to acetylsalicylic acid&#xD;
&#xD;
          -  Patients with acute or chronic infectious sinusitis&#xD;
&#xD;
          -  Patients with asthma, that need treatment with beta-2 agonists more than twice per&#xD;
             week&#xD;
&#xD;
          -  Patients with glaucoma&#xD;
&#xD;
          -  Patients with history or renal and/or hepatic failure&#xD;
&#xD;
          -  Patients with known platelets dysfunction due to any disease or to drugs (purpura&#xD;
             thrombocytopenic idiopathic, use of anticoagulants, use of antiplatelets drugs)&#xD;
&#xD;
          -  Patients with any oncological disease&#xD;
&#xD;
          -  Patients with nasal septal deviation causing alteration of the nasal flux, polyps,&#xD;
             anatomic/structural alterations (ex., tumors, leishmaniosis, etc.)&#xD;
&#xD;
          -  Patients with any cardiovascular disease&#xD;
&#xD;
          -  Patients with arterial hypertension&#xD;
&#xD;
          -  Patients requiring halogenates anesthetics&#xD;
&#xD;
          -  Patients with diabetes mellitus&#xD;
&#xD;
          -  Patients with hyperthyroidism&#xD;
&#xD;
          -  Patients with prostatic hypertrophy&#xD;
&#xD;
          -  Patients with epilepsy or any other seizure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/262/262.254_U02-3414.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Epinastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

